UBS Group
BNTCW

UBS Group’s Benitec Biopharma Limited BNTCW Stock Holding History

UBS Group’s Portfolio BNTCW Stock Details BNTCW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-844
Closed – – 8368
2017
Q4 		$0 Buy
844
+459
+119% +$170 ﹤0.01% 8245
2017
Q3 		$0 Hold
385
– – ﹤0.01% 8152
2017
Q2 		$0 Buy
+385
New +$134 ﹤0.01% 8177
2017
Q1 		– Sell
-279
Closed – – 8175
2016
Q4 		$0 Buy
+279
New +$28 ﹤0.01% 8189

Other funds holding BNTCW

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

UBS Group's BNTCW Position: Q1 2018 in Review

UBS Group sold out of Benitec Biopharma Limited (BNTCW) in Q1 2018, closing a stake of 844 shares.

UBS Group first reported a position in BNTCW in Q4 2016 and held it in 4 quarters. The position peaked at $0 in Q4 2017. 1 fund tracked by Wall St. Rank holds BNTCW as of Q1 2018.

  • UBS Group reported no remaining Benitec Biopharma Limited position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 844 Benitec Biopharma Limited shares in Q1 2018.
  • UBS Group first reported a position in Benitec Biopharma Limited in Q4 2016 and held it in 4 quarters.
  • UBS Group's Benitec Biopharma Limited position peaked at $0 in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Benitec Biopharma Limited as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.